Foodborne botulism treated with heptavalent botulism antitoxin

Annals of Pharmacotherapy

Volumn 47, Issue 2, 2013, Pages

  Hill, Stanley E ^a,b,c   Iqbal, Raza ^a   Cadiz, Christine L ^c   Le, Jennifer ^a,b  

^a LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; BOTULINUM ANTISERUM; BOTULINUM TOXIN; METRONIDAZOLE;

ADULT; ANAPHYLAXIS; ARTICLE; ARTIFICIAL VENTILATION; BLOOD LEVEL; BLURRED VISION; BOTULISM; CASE REPORT; DIPLOPIA; DRUG HYPERSENSITIVITY; DRUG USE; DYSARTHRIA; DYSPHAGIA; FOOD POISONING; HUMAN; INTENSIVE CARE UNIT; MALE; MUSCLE STRENGTH; MUSCLE WEAKNESS; NAUSEA; PARALYSIS; PRIORITY JOURNAL; PTOSIS; RESPIRATORY DISTRESS; SERUM SICKNESS;

EID: 84873957522     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R646     Document Type: Article

References (21)

1. Sobel J. Botulism. Clin Infect Dis 2005;41:1167-73.
2. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001;285: 1059-70.
3. Dembek ZF, Smith LA, Rusnak JM. Botulinum toxin. In: Dembek ZF, ed. Medical aspects of biological warfare. Washington, DC: Office of Surgeon General, Borden Institute, 2008:337-53.
4. Botulism in the United States, 1899-1996. Handbook for epidemiologists, clinicians, and laboratory workers. Atlanta, GA: Centers for Disease Control and Prevention, 1998.
5. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med 1998;129:221-8.
6. Sobel J, Tucker N, Sulka A, McLaughlin J, Maslanka S. Foodborne botulism in the United States, 1990-2000. Emerg Infect Dis 2004;10:1606-11.
7. Hughes JM, Blumenthal JR, Merson MH, Lombard GL, Dowell VR Jr, Gangarosa EJ. Clinical features of types A and B food-borne botulism. Ann Intern Med 1981;95:442-5.
8. Notice of CDC's discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. MMWR Morb Mortal Wkly Rep 2011;60: 1454-5.
9. Rusnak JM, Smith LA. Botulinum neurotoxin vaccines: past history and recent developments. Hum Vaccin 2009;5:794-805.
10. Hart MK, Saviolakis GA, Welkos SL, House RV. Advanced development of the rF1V and rBV A/B vaccines: progress and challenges. Adv Prev Med 2012;2012:731604.
11. Dynport Vaccine Company. Press release page. CSC's DynPort Vaccine Company releases results for Phase 2 botulinum vaccine clinical trial. http://www.csc.com/dvc/press_releases/77621-csc_s_dynport_vaccine_ company_releases_results_for_phase_2_botulinum_vaccine_clinical_trial (accessed 2012 Jul 6).
12. Swenson JM, Thornsberry C, McCroskey LM, Hatheway CL, Dowell VR Jr. Susceptibility of Clostridium botulinum to thirteen antimicrobial agents. Antimicrob Agents Chemother 1980;18:13-9.
13. Davis LE, Johnson JK, Bicknell JM, Levy H, McEvoy KM. Human type A botulism and treatment with 3,4-diaminopyridine (abstract). Electromyogr Clin Neurophysiol 1992;32:379-83.
14. Dock M, Ben Ali A, Karras A, et al. [Treatment of severe botulism with 3,4-diaminopyridine] (abstract). French. Presse Med 2002;31:601-2.
15. Ball AP, Hopkinson RB, Farrell ID, et al. Human botulism caused by Clostridium botulinum type E: the Birmingham outbreak. Q J Med 1979; 48:473-91.
16. Investigational heptavalent botulism antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb Mortal Wkly Rep 2010;59:299.
17. Centers for Disease Control and Prevention. IND Protocol: Use of NP-018 heptavalent equine-based botulinum antitoxin (H-BAT) after exposure to Clostridium botulinum toxin or other closely-related botulinum toxin-producing Clostridia species due to a naturally occurring outbreak or isolated incident. BB-IND 6750, August 16, 2010:version 7.0.
18. Tacket CO, Shandera WX, Mann JM, Hargett NT, Blake PA. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984;76:794-8.
19. Tantawichien T, Benjavongkulchai M, Wilde H, et al. Value of skin testing for predicting reactions to equine rabies immune globulin. Clin Infect Dis 1995;21:660-2.
20. 2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin Infect Dis 1996;23:337-40.
21. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 1980;69:567-70.